To cite this paper use one of the standards below:
Background: Asthma is a chronic common condition that affects 235 million people around the globe, according to the World Health Organization1. There are several endotypes of asthma, including mixed-granulocytic type that has high eosinophil and neutrophil counts, frequently related to a more severe airway obstruction, more frequent exacerbations and higher health related costs. For this type of asthma, there is no specific treatment available2. Biseugenol, isolated from Nectandra leucantha (Lauraceae), displayed immunomodulatory activity3 but its effects for the treatment of mixed-granulocytic asthma have not previously been reported.
Objective: To evaluate the anti-asthmatic effects of biseugenol on experimental mice models of mixed-granulocytic asthma through the assessment of respiratory mechanics and inflammation parameters on bronchoalveolar lavage fluid.
Methods: N. leucantha leaves was extracted with n-hexane. After evaporation under reduced pressure, the n-hexane extract was subjected to successive chromatographic steps to afford biseugenol (98% of purity as determinate by HPLC). Its chemical structure was confirmed by analysis of NMR and HRESIMS spectra4. BALB/C male mice were immunized using OVA (grade V), in the presence of Freund’s Complete Adjuvant, administered s.c., on day 1 of protocol. Challenges were carried on days 21, 22 and 23 after the immunization, with intranasal OVA grade II solution. Biseugenol (20 mg.kg–1) was administered intraperitoneally during the last 4 days of study protocol after the OVA challenges. Lung function was evaluated through the analysis of Newtonian Resistance (Rn), Tissular Dumping (G) and Elastance (H), using a rodent ventilator (FlexVent). Inflammatory parameters on the bronchoalveolar lavage fluid were evaluated by microscopic techniques.
Results: Biseugenol (20 mg.kg–1) resulted on significant reduction of total cell (Δ = 9.89x104/mL; P < 0.001), eosinophil (Δ = 6.09x104/mL; P < 0.05) and neutrophil (Δ=2.40x104 /mL; P < 0.001) count of bronchoalveolar lavage fluid in ovalbumin-sensitized mice, with no statistically difference from dexamethasone regarding reduction on eosinophil and neutrophil concentrations (P = n.s.). As for lung function parameters, biseugenol significantly reduced the maximal response to methacholine in both central (ΔRn = 1.67 cmH2O.s/mL; P < 0.05) and peripheral (ΔG = 4.60 cmH2O.s/mL; P<0.05) airways in comparison to the ovalbumin-sensitized group, with similar efficacy to positive control dexamethasone (P = n.s.). Airway hyperresponsiveness to intravenous methacholine was reduced with biseugenol but was inferior to dexamethasone in higher doses of methacholine. No changes were observed on elastance in any group evaluated (P = n.s.). No safety concerns or deaths occurred to the animals during the study protocol.
Conclusion: Biseugenol at the dose of 20 mg.kg–1 showed potential anti-asthmatic effects, as observed through the reduction of inflammation on bronchoalveolar lavage fluid and airway hyper-responsiveness in experimental models of mixed-granulocytic asthma.
References: 1WHO – World Health Organization. Facts about asthma. Available at: http://www.who.int/news-room/fact-sheets/detail/asthma. Accessed 28/08/2019. 2Svenningsen S et al. Front. Med. 2017;4:158. 3da Costa-Silva TA, et al. J Nat Prod. 2015 78(4):653-7. 4Rodrigues LC, et al. Chem. Biodiversity. 2016;13: 870-4.
Acknowledgments: CAPES, CNPq and FAPESP
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper